AUSTRALIAN-OWNED consumer pharmaceutical company First Pharma has flagged its expansion ambitions with the acquisition of pharmacy-only skin care company Kenkay Pharmaceuticals.
Kenkay has been a leader in the sorbolene market as well as a wide range of dermatological products for the whole family.
First Pharma ceo Justin Ooi (pictured) described the Kenkay acquisition as "a key milestone that adds a well-established Australian-made product range to the First Pharma stable of brands.
"Kenkay is a great strategic fit, delivering a highly regarded suite of products to bolster our presence and offering in the growing skin care market," he said.
Ooi added that the company has ambitious plans for further product development and reaffirmed his commitment to increase support for retail pharmacies.
"We look forward to connecting with our customers to learn how we can improve an already excellent product range.
"Pharmacists can continue to order Kenkay brands from wholesalers or contact First Pharma for some great opening deals on our key lines," he said.
The purchase of Kenkay follows First Pharma's acquisitions of KraveGone mouth spray (PD 27 Feb 2018), an innovative OTC product that suppresses cravings for sweet foods.
"Strengthening our portfolio and pipeline through targeted acquisitions and investments remains a priority for First Pharma," said First Pharma executive chairman, Andrew Howden.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jun 18
